Literature DB >> 25514921

Paracrine factors from mesenchymal stem cells attenuate epithelial injury and lung fibrosis.

Qinqin Shen1, Bing Chen2, Zhifeng Xiao2, Lifen Zhao1, Xuefeng Xu1, Xuan Wan1, Mulan Jin3, Jianwu Dai2, Huaping Dai1.   

Abstract

Paracrine factors are currently considered to be the major mechanism through which mesenchymal stem cells (MSCs) exert their actions. The aim of this study was to investigate the protective effects of conditioned medium (CM) from bone marrow mesenchymal stem cells (MSC) on bleomycin (BLM)‑induced lung injury and fibrosis, both in vitro and in vivo. A549 human non‑small cell lung cancer epithelial cells were cultured in serum‑free medium, or MSC‑CM, both with or without BLM. The protective effects of MSC‑CM was determined by MTT assay to assess cell viability and Annexin V‑PE to assess apoptosis. Rats were intratracheally injected with MSC‑CM, saline, or conditioned medium from fibroblasts on day 0 and day 3 after intratracheal administration of BLM, and were sacrificed on day 28. Lung injury and fibrosis were assessed by histological assessment, Ashcroft score, and hydroxyproline assay; lung cell apoptosis was detected using terminal deoxynucleotidyl transferase dUTP nick end labeling assay. In comparison to the control group (0.17±0.01), 8 and 16% MSC‑CM had a significant stimulatory effect on A549 cellular proliferation (0.24±0.03 and 0.24±0.04, respectively, P<0.01). A549 cells cultured with MSC‑CM were protected from BLM‑induced apoptosis, 23.43±3.76% vs. 38.06±4.32%; (P<0.05). In the BLM‑challenged rats, MSC‑CM was shown to protect against lung fibrosis in terms of lung inflammation, fibrotic scores, collagen deposition, and cell apoptosis. This data suggests that MSCs are capable of protecting against lung injury and fibrosis both in vitro and in vivo through a paracrine anti‑inflammatory mechanism. MSC‑CM may provide a novel approach for the treatment of lung fibrosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25514921     DOI: 10.3892/mmr.2014.3092

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  28 in total

Review 1.  Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value.

Authors:  John G Laffey; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

2.  Histological and Physiological Studies of the Effect of Bone Marrow-Derived Mesenchymal Stem Cells on Bleomycin Induced Lung Fibrosis in Adult Albino Rats.

Authors:  Dina Mohamed Zakaria; Noha Mahmoud Zahran; Samia Abdel Aziz Arafa; Radwa Ali Mehanna; Rehab Ahmed Abdel-Moneim
Journal:  Tissue Eng Regen Med       Date:  2020-10-22       Impact factor: 4.169

3.  Bone Marrow Mesenchymal Stem Cell-Based Engineered Cartilage Ameliorates Polyglycolic Acid/Polylactic Acid Scaffold-Induced Inflammation Through M2 Polarization of Macrophages in a Pig Model.

Authors:  Jinping Ding; Bo Chen; Tao Lv; Xia Liu; Xin Fu; Qian Wang; Li Yan; Ning Kang; Yilin Cao; Ran Xiao
Journal:  Stem Cells Transl Med       Date:  2016-06-08       Impact factor: 6.940

4.  Hepatocyte Growth Factor Is Required for Mesenchymal Stromal Cell Protection Against Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Emer F Cahill; Helen Kennelly; Fiona Carty; Bernard P Mahon; Karen English
Journal:  Stem Cells Transl Med       Date:  2016-07-07       Impact factor: 6.940

Review 5.  Mesenchymal stem cells: A double-edged sword in radiation-induced lung injury.

Authors:  Yi Yao; Zhongliang Zheng; Qibin Song
Journal:  Thorac Cancer       Date:  2017-12-13       Impact factor: 3.500

Review 6.  Mesenchymal stem cells in idiopathic pulmonary fibrosis.

Authors:  Xiaohong Li; Shaojie Yue; Ziqiang Luo
Journal:  Oncotarget       Date:  2017-05-23

7.  Oncostatin M-Preconditioned Mesenchymal Stem Cells Alleviate Bleomycin-Induced Pulmonary Fibrosis Through Paracrine Effects of the Hepatocyte Growth Factor.

Authors:  Ying-Wei Lan; Si-Min Theng; Tsung-Teng Huang; Kong-Bung Choo; Chuan-Mu Chen; Han-Pin Kuo; Kowit-Yu Chong
Journal:  Stem Cells Transl Med       Date:  2016-10-18       Impact factor: 6.940

Review 8.  Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Authors:  Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn
Journal:  World J Stem Cells       Date:  2017-03-26       Impact factor: 5.326

9.  Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?

Authors:  Elia Bari; Ilaria Ferrarotti; Laura Saracino; Sara Perteghella; Maria Luisa Torre; Luca Richeldi; Angelo Guido Corsico
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

10.  Mesenchymal stem cells are sensitive to bleomycin treatment.

Authors:  Nils H Nicolay; Alexander Rühle; Ramon Lopez Perez; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-05-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.